


Fund Objective

This Fund seeks to achieve capital appreciation by investing in equities and securities of global pharmaceutical companies. Emphasis is placed on large, multinational pharmaceutical companies, though a smaller portion of assets is invested in innovative biotechnology stocks. The fund invests all or substantially all its assets into DWS Health Care Typ O Fund*.

**DWS Pharma-Aktien Typ O will be renamed DWS Health Care Typ O with effect from 30 April 2010*

Fund Performance (\$ Bid-to-Bid returns)



	Manulife Golden Life Sciences Fund (%)	MSCI ACWI Healthcare Net USD (%)
1 month	-2.10	0.06
3 months	-4.20	1.03
6 months	-12.53	-9.05
1 year	-9.01	-1.41
3 years	-9.82	-6.34
5 years	-6.11	-1.61
Since Inception	-2.30	0.16

Source: Morningstar • Performance are NAV-NAV in SGD as at 31 Aug 10 • Performance figures for 1 mth till 1 yr show the % change, those exceeding 1 yr show the average annual compounded return.

Deutsche Asset Management (Asia) Limited was appointed fund manager of the Golden Life Sciences Funds on 8 August 2003.

The CPF interest rate for the Ordinary Account (OA) is based on the 12-month fixed deposit and month-end savings rates of the major local banks. Under the CPF Act, the Board pays a minimum interest of 2.5% p.a. when this interest formula yields a lower rate. From 1 Jan 08, the new interest rate for the Special, Medisave & Retirement Accounts (SMRA) will be pegged to the yield of 10-year Singapore government bond plus 1%. For 2008 and 2009, the minimum interest rate for the SMRA will be 4% p.a. After 2009, the 2.5% p.a. minimum interest rate, as prescribed by the CPF Act, will apply to SMRA. In addition, from 1 Jan 08, the CPF Board will pay an extra interest of 1% per annum on the first \$60,000 of a CPF member's combined balances, including up to \$20,000 in the OA. From 1 April 08, the first \$20,000 in the Ordinary Account will not be allowed to be invested under the CPF Investment Scheme. And from 1 May 09, the first \$30,000 in the Special Account will not be allowed to be invested under the CPF Investment Scheme and further raised to \$40,000 from 1 July 2010.

Key Information

Launch Date	: 1 March 2002	Launch Price	: S\$1.00
Bid Price	: *S\$0.7771	Management Fee	: 1.50% p.a.
Offer Price	: *S\$0.8180 @ 5% sales charge (RP plans) / *S\$0.8011 @ 3% sales charge (SP plans)	Dealing	: Daily
CPFIS Risk Classification:	Higher Risk - Narrowly Focused	Bid-Offer Spread	: 5% (RP) / 3% (SP)
Subscription	: CPFIS-OA/SRS/Cash		
Price published In	: The Straits Times, Business Times, Lianhe Zaobao, www.manulife.com.sg		
Min Investment	: S\$5000 (single premium), S\$100 (monthly premium), S\$500 (top-up)		

Important Information: This report is prepared by Manulife (Singapore) Pte Ltd and is provided for information purposes only. Past performance is not necessarily a guide to future performance.

Asset Allocation (in %)*

Net Asset Value = S\$8,047,468.49

USA	61.70
Switzerland	6.90
Germany	6.40
Great Britain	5.10
Ireland	4.30
Japan	3.30
Denmark	2.50
Brazil	1.90
China	1.90
France	1.70
India	1.40
Other Countries	1.30
Warrants	0.20
Cash and other assets	1.50

Top Ten Holdings (in %)*

McKesson Corp.	3.70
Novartis AG	3.50
Abbott Laboratories	3.40
Mylan Inc.	3.30
Merck & Co. Inc.	3.30
Pfizer Inc.	3.20
Johnson & Johnson	3.10
Covidien PLC	2.90
Medco Health Solutions	2.80
Astrazeneca PLC	2.70

Fund Manager's Comments

In an overall market environment which remained extremely uncertain about the weakness of the US economy, the listed healthcare sector slightly outperformed the broad stock market for the month. Because of the difficulties on the job market, the US healthcare sector in particular is seeing a trend of people avoiding or postponing visits to the doctor or hospital in order to avoid private co-payments. The effects of this can now be seen especially clearly in the weak figures of the medical technology sector. The Fund increased the weighting of health insurance companies since they are expected to profit from this trend, at least in the short term. The market has thus far greeted Sanofi's planned takeover of the biotechnology company Genzyme with little enthusiasm, as few synergies are assumed in spite of lower financing costs.